Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Riess

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2024
Mapping EGFR Exon 20 Resistance Mutations: An Intricate LandscapeSurbhi Singhal, David Gandara, Jonathan W Riess
Clinical Lung Cancer|April 21, 2021
Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a ModelJonathan W Riess, Christian Rolfo, David R Gandara
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road WiselyAntonio Calles, Jonathan W Riess, Julie R Brahmer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung CancerJonathan W Riess, Primo N Lara, David R Gandara
Current Problems in Cancer|February 10, 2024
Targeting MEK in non-small cell lung cancerMatthew S Lara, Collin M Blakely, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
KRAS G12C Inhibitors: New Drugs, A New HopeSurbhi Singhal, Shiruyeh Schokrpur, David Gandara, et al.
JAMA Oncology|June 15, 2018
In Search of an Oncogene Driver for Squamous Lung CancerDavid R Gandara, Jonathan W Riess, Primo N Lara
Clinical Lung Cancer|June 1, 2021
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and CrizotinibJingran Ji, Anupam Mitra, D Ross Camidge, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinibJonathan W Riess, Seema Nagpal, Joel W Neal, et al.
JCO Precision Oncology|April 11, 2024
CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case ReportEbaa Al-Obeidi, Karen Kelly, David R Gandara, et al.
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2024
Mapping EGFR Exon 20 Resistance Mutations: An Intricate LandscapeSurbhi Singhal, David Gandara, Jonathan W Riess
Clinical Lung Cancer|April 21, 2021
Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a ModelJonathan W Riess, Christian Rolfo, David R Gandara
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road WiselyAntonio Calles, Jonathan W Riess, Julie R Brahmer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung CancerJonathan W Riess, Primo N Lara, David R Gandara
Current Problems in Cancer|February 10, 2024
Targeting MEK in non-small cell lung cancerMatthew S Lara, Collin M Blakely, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
KRAS G12C Inhibitors: New Drugs, A New HopeSurbhi Singhal, Shiruyeh Schokrpur, David Gandara, et al.
JAMA Oncology|June 15, 2018
In Search of an Oncogene Driver for Squamous Lung CancerDavid R Gandara, Jonathan W Riess, Primo N Lara
Clinical Lung Cancer|June 1, 2021
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and CrizotinibJingran Ji, Anupam Mitra, D Ross Camidge, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinibJonathan W Riess, Seema Nagpal, Joel W Neal, et al.
JCO Precision Oncology|April 11, 2024
CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case ReportEbaa Al-Obeidi, Karen Kelly, David R Gandara, et al.
Pageof 14